Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
PEARL-III and PEARL-IVTwo phase 3, randomized trials find that 12 weeks of ABT-450/r-ombitasvir and dasabuvir with or without ribavirin is effective
in patients with chronic HCV genotype 1 infection and no cirrhosis.
